Company / Current Liabilities per Share
GT Biopharma, Inc. Current Liabilities per Share History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$8.55
FY2020
5-year range
$0.05 / $25.71
FY2016-FY2020
Trend
-66.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $25.49 to $8.55 over the past 4 years.
Based on SEC 10-K filings.
8.55 in FY2020 with a 5-year CAGR of -7.5%.
Improved from $25.49 to $8.55 over the past 4 years.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -30.7%
- 5-Year CAGR
- -7.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, current liabilities per share decreased 66.7% year-over-year.
- Peak current liabilities per share was recorded in FY2017.
- Lowest current liabilities per share in the period was in FY2013.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $8.55 | -66.7% |
| FY2017 | $25.71 | +0.8% |
| FY2016 | $25.49 | +102.2% |
| FY2015 | $12.60 | +24114.2% |
| FY2014 | $0.05 | +308.1% |
| FY2013 | $0.01 | -47.7% |
| FY2012 | $0.02 | -30.3% |
| FY2011 | $0.03 | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026